Related Experiment Video

Updated: Aug 5, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

From Concept to Clinic: Vepdegestrant (ARV 471) Becomes the First Approved PROTAC Drug

Miklós Bege1, Miklós Lovas1,2, Anikó Borbás1

  • 1Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem Tér 1, H-4032 Debrecen, Hungary.

Pharmaceutics
|July 28, 2026
PubMed

Insights

Vepdegestrant is the first Proteolysis Targeting Chimera (PROTAC) drug approved for estrogen receptor-mutated breast cancer. This oral medication offers a new therapeutic option by degrading harmful proteins, addressing limitations of classical treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Breast cancer (BC) presents a significant global health challenge with limited efficacy of traditional therapies.
  • New therapeutic strategies are essential for effective BC treatment.
  • Proteolysis targeting chimeras (PROTACs) offer a novel approach by inducing targeted protein degradation.

Purpose of the Study:

  • To provide a concise overview of vepdegestrant, the first FDA-approved PROTAC drug.
  • To summarize the structure, mechanism of action, and pharmacokinetic/pharmacological data of vepdegestrant.
  • To highlight vepdegestrant's role in treating specific types of advanced or metastatic breast cancer.

Main Methods:

  • Review of available scientific literature and clinical data on vepdegestrant.
  • Analysis of vepdegestrant's molecular structure and its PROTAC mechanism.
  • Evaluation of pharmacokinetic and pharmacological properties relevant to clinical application.

Main Results:

  • Vepdegestrant is an orally administered PROTAC targeting the estrogen receptor (ER).
  • It is approved for adults with ESR1-mutated advanced or metastatic breast cancer.
  • Vepdegestrant represents a breakthrough as the first approved PROTAC therapeutic.

Conclusions:

  • Vepdegestrant signifies a major advancement in breast cancer therapy through PROTAC technology.
  • Its oral administration and targeted degradation mechanism offer potential advantages over conventional treatments.
  • Further understanding of its pharmacokinetic and pharmacological profile is crucial for optimizing patient outcomes.
Keywords:
ARV 471PROTACSERDVeppanuTMbreast cancerendocrine therapyestrogen receptorprotein degradationtargeted tumor therapyvepdegestrant

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...